Form D · Biotechnology
EPOCH Epigenetics, Inc.
Baltimore, MD · CIK 0002068186
Offering snapshot reported Jun 16, 2025 · SEC filing
- Reported sold
- $72.5K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 20, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2025 | Initial | $72,500 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-548984
Source: Form D, filed Jun 16, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Neil Hermansen | Director, Executive |
| Joseph Swiader | Director, Executive |
| Eric Van Gieson | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4 N. Martin Luther King Jr. Blvd. Floor 3
Baltimore, MD, 21201
Baltimore, MD, 21201